Pinnacle Associates’s CollPlant Biotechnologies CLGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-73,166
| Closed | -$255K | – | 968 |
|
|
2026
Q2 | $255K | Buy |
73,166
+18,143
| +33% | +$69.9K | ﹤0.01% | 858 |
|
|
2026
Q1 | $295K | Sell |
55,023
-696
| -1% | -$7.02K | ﹤0.01% | 807 |
|
|
2025
Q4 | $780K | Buy |
55,719
+5,000
| +10% | +$102K | 0.01% | 566 |
|
|
2025
Q3 | $1.36M | Hold |
50,719
| – | – | 0.02% | 458 |
|
|
2025
Q2 | $690K | Buy |
50,719
+1,800
| +4% | +$37.3K | 0.01% | 570 |
|
|
2025
Q1 | $1.26M | Sell |
48,919
-50
| -0.1% | -$1.76K | 0.02% | 453 |
|
|
2024
Q4 | $1.76M | Buy |
48,969
+2,158
| +5% | +$87.7K | 0.02% | 390 |
|
|
2024
Q3 | $2.99M | Sell |
46,811
-9,625
| -17% | -$471K | 0.05% | 297 |
|
|
2024
Q2 | $2.8M | Buy |
56,436
+3,390
| +6% | +$188K | 0.04% | 314 |
|
|
2024
Q1 | $2.84M | Buy |
53,046
+6,235
| +13% | +$337K | 0.04% | 321 |
|
|
2023
Q4 | $2.99M | Sell |
46,811
-1,020
| -2% | -$55.8K | 0.05% | 300 |
|
|
2023
Q3 | $2.66M | Sell |
47,831
-634
| -1% | -$41.9K | 0.05% | 311 |
|
|
2023
Q2 | $3.95M | Buy |
+48,465
| New | +$3.53M | 0.07% | 258 |
|
Pinnacle Associates's CLGN Position: Q3 2026 in Review
Pinnacle Associates sold out of CollPlant Biotechnologies (CLGN) in Q3 2026, closing a stake of 73,166 shares — an estimated $255K sold.
Pinnacle Associates first reported a position in CLGN in Q2 2023 and held it in 13 quarters. The position peaked at $3.95M in Q2 2023. 0 funds tracked by Wall St. Rank hold CLGN as of Q3 2026.
- Pinnacle Associates reported no remaining CollPlant Biotechnologies position as of Q3 2026 after selling out during the quarter.
- Pinnacle Associates sold 73,166 CollPlant Biotechnologies shares in Q3 2026, an estimated $255K.
- Pinnacle Associates first reported a position in CollPlant Biotechnologies in Q2 2023 and held it in 13 quarters.
- Pinnacle Associates's CollPlant Biotechnologies position peaked at $3.95M in Q2 2023.
- 0 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q3 2026.
Based on Pinnacle Associates's 13F filing for Q3 2026, filed 20 Oct 2026.